Business Wire

Pink Lipsticks and Green Thumbs: Mary Kay Inc. Celebrates 60 Years of Sustainable Beauty With Special Tree Planting Event in Lewisville

14.5.2024 19:00:00 EEST | Business Wire | Press release

Share

Mary Kay Inc., a corporate leader in global sustainability, is strengthening its roots in Lewisville. On May 10, the company partnered with the Arbor Day Foundation and Keep Lewisville Beautiful to host a tree planting event at Railroad Park to celebrate Mother Nature and Mother’s Day.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240514127551/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Trees planted at Railroad Park directly impact Lewisville communities by providing important ecosystem benefits in the Trinity River watershed. (Photo: Mary Kay Inc.)

“Through partnerships with organizations like the Arbor Day Foundation, Mary Kay is making positive environmental impact in ecosystems where we operate around the world,” said Ryan Rogers, CEO of Mary Kay, Inc., and grandson of Mary Kay Ash. “But change starts in your own backyard. We enjoyed ‘sprucing’ up the community by planting trees that will benefit local families for generations to come.”

Mary Kay volunteers planted 60 native trees along the trails and waterways in Railroad Park, symbolizing the company’s 60th anniversary of enriching the lives of women and their families worldwide and protecting the planet. The park is four miles from Mary Kay’s state-of-the-art Richard R. Rogers (R3) Manufacturing/R&D Center. Trees planted at this location directly impact Lewisville communities by providing much-needed shade in community spaces, enhancing the beautification of recreational areas, and providing important ecosystem benefits in the Trinity River watershed.

"We are thrilled to see Mary Kay contribute to the tree canopy of Lewisville,” said TJ Gilmore, Mayor of Lewisville. “This initiative is not only a breath of fresh air for our city but a testament to the flourishing partnership between our community and a corporation that continuously gives back. Together, we’re making Lewisville a better place to live and work."

Mary Kay’s partnership with the Arbor Day Foundation stretches back more than 16 years—and in that time, the company has helped plant 1.4 million trees around the world. Arbor Day Foundation is the world’s largest membership nonprofit dedicated to planting trees.

“The Arbor Day Foundation is dedicated to helping our local planting partners unlock the transformative power of trees in their community,” said Dan Lambe, Chief Executive of the Arbor Day Foundation. “Trees clean our air, cool our cities, and improve the lives of the people around them. We’re happy to partner again with Mary Kay and Keep Lewisville Beautiful to maximize the impact of the urban canopy and inspire more people to engage with nature in a meaningful way.”

Keep Lewisville Beautiful is a local environmental nonprofit that partners with organizations to plant trees and provide residents opportunities to care for Lewisville’s tree canopy on public lands.

“Tree planting is an investment in our community’s future,” said Amy Wells, Executive Director of Keep Lewisville Beautiful. “These trees will help create shade for families visiting Railroad Park, provide habitat to local wildlife, and will provide a multitude of ecological benefits for our local environment. Keep Lewisville Beautiful is excited to partner with Mary Kay and the Arbor Day Foundation to increase Lewisville’s tree canopy and make a visible difference in our community with Mary Kay volunteers. Their donation to our community and KLB will go a long way towards keeping Lewisville beautiful.”

Following the planting, the Lewisville Parks Department is committed to long-term maintenance and upkeep of the trees with supplemental watering, pruning, and care.

Did you know:

  • R3 Manufacturing/R&D Center in Lewisville is named in honor of Mary Kay Inc.’s cofounder and Mary Kay Ash’s son, Richard R. Rogers.
  • Built on 26 acres of land, R3 features state-of-the-art R&D laboratories and cutting-edge manufacturing technology.
  • 57% of products manufactured at R3 are exported to Mary Kay’s international markets.
  • R3 production capacity is up to 1.1 million products per day. The facility boasts 20 product-packaging lines and 21 processing vessels and mixing tanks.
  • R3 is LEED Building Design and Construction Silver-Certified facility.

About Mary Kay

Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.

About the Arbor Day Foundation

Founded in 1972, the Arbor Day Foundation is the largest nonprofit membership organization dedicated to planting trees. Together with our partners, we have helped plant more than 500 million trees in neighborhoods, communities, cities, and forests throughout the world. Our vision is to lead toward a world where trees are used to solve issues critical to survival. Through our members, partners and programs, the Arbor Day Foundation inspires people across the globe to plant, nurture and celebrate trees. More information is available at arborday.org.

About Keep Lewisville Beautiful

Keep Lewisville Beautiful (KLB) is a non-profit and award-winning affiliate of Keep America Beautiful and Keep Texas Beautiful. KLB’s mission is to “engage the citizens of Lewisville through service and education to enhance their community environment”. Our vision is to partner with the community to promote environmental quality, making Lewisville the best place to live, work, and play. Annually, KLB volunteers contribute over 10,000 volunteer hours towards litter abatement, environmental education, and beautification programs, and remove 25+ TONS of trash from community green spaces and waterways. Learn more at keeplewisvillebeautiful.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye